Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR [Yahoo! Finance]
Glaukos Corporation (GKOS)
Last glaukos corporation earnings: 2/27 04:15 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.glaukos.com/investors/investor-overview/default.aspx
Company Research
Source: Yahoo! Finance
on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved an NDA labeling supplement allowing for re-administration of iDose ® TR using a repeat treatment protocol. The FDA approval is in response to Glaukos' 2025 NDA labeling supplement application, and reflects accumulated clinical evidence supporting the safety and tolerability of repeat use for iDose TR "We are pleased to announce this important labeling enhancement for iDose TR , which should help expand access for patients who may benefit from repeat treatment and provide physicians with greater flexibility in managing their glaucoma patients over time," said Thomas Burns, Glaukos chairman and chief executive officer. "This approval further validates iDose TR's established and proven safety profile and reinforces its leading position in addressing the strong and growing demand within the ophthalmic community for safe,
Show less
Read more
Impact Snapshot
Event Time:
GKOS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GKOS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GKOS alerts
High impacting Glaukos Corporation news events
Weekly update
A roundup of the hottest topics
GKOS
News
- Wells sees potential upside after Glaukos' iDose repeat dosing label approved [Yahoo! Finance]Yahoo! Finance
- Glaukos (NYSE:GKOS) had its price target raised by analysts at BTIG Research from $123.00 to $131.00. They now have a "buy" rating on the stock.MarketBeat
- Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TRBusiness Wire
- What Makes Glaukos (GKOS) a Good Investment? [Yahoo! Finance]Yahoo! Finance
- Glaukos (NYSE:GKOS) had its price target raised by analysts at Stifel Nicolaus from $115.00 to $160.00. They now have a "buy" rating on the stock.MarketBeat
GKOS
Earnings
- 10/29/25 - Beat
GKOS
Sec Filings
- 1/26/26 - Form 4
- 1/26/26 - Form 4
- 1/23/26 - Form 4
- GKOS's page on the SEC website